Arcellx (ACLX) Competitors $58.59 -3.85 (-6.17%) Closing price 04:00 PM EasternExtended Trading$58.52 -0.07 (-0.11%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACLX vs. SMMT, ITCI, GMAB, RDY, MRNA, VTRS, ASND, QGEN, ROIV, and LNTHShould you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Arcellx vs. Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Ascendis Pharma A/S Qiagen Roivant Sciences Lantheus Summit Therapeutics (NASDAQ:SMMT) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Do analysts recommend SMMT or ACLX? Summit Therapeutics presently has a consensus target price of $35.44, suggesting a potential upside of 104.17%. Arcellx has a consensus target price of $110.67, suggesting a potential upside of 88.88%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcellx 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Does the MarketBeat Community prefer SMMT or ACLX? Summit Therapeutics received 240 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 58.56% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30858.56% Underperform Votes21841.44% ArcellxOutperform Votes6882.93% Underperform Votes1417.07% Does the media prefer SMMT or ACLX? In the previous week, Summit Therapeutics had 5 more articles in the media than Arcellx. MarketBeat recorded 8 mentions for Summit Therapeutics and 3 mentions for Arcellx. Arcellx's average media sentiment score of 1.33 beat Summit Therapeutics' score of 0.64 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcellx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SMMT or ACLX more profitable? Summit Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Arcellx -25.94%-8.28%-5.21% Which has preferable earnings & valuation, SMMT or ACLX? Arcellx has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K18,294.46-$614.93M-$0.31-56.00Arcellx$107.94M29.82-$70.69M-$2.00-29.30 Do institutionals & insiders have more ownership in SMMT or ACLX? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by company insiders. Comparatively, 6.2% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, SMMT or ACLX? Summit Therapeutics has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. SummaryArcellx beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACLX vs. The Competition Export to ExcelMetricArcellxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.22B$2.83B$5.28B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-82.5229.1822.8717.48Price / Sales29.82420.20357.3785.27Price / CashN/A168.6838.1634.64Price / Book5.883.496.233.79Net Income-$70.69M-$72.06M$3.20B$247.10M7 Day Performance-13.79%-12.86%-7.91%-7.31%1 Month Performance-10.73%-20.18%-2.94%-10.19%1 Year Performance-5.52%-34.28%3.18%-7.40% Arcellx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACLXArcellx1.9307 of 5 stars$58.59-6.2%$110.67+88.9%-1.2%$3.22B$107.94M-82.5280News CoveragePositive NewsGap DownHigh Trading VolumeSMMTSummit Therapeutics2.6374 of 5 stars$19.29-5.1%$35.44+83.7%+378.7%$14.23B$700,000.00-68.89110Gap DownITCIIntra-Cellular Therapies3.4634 of 5 stars$131.92+0.1%$106.08-19.6%N/A$14.05B$680.50M-151.63560Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeGMABGenmab A/S3.7504 of 5 stars$19.58-1.6%$41.33+111.1%-34.3%$12.96B$21.53B11.251,660Analyst DowngradeGap DownRDYDr. Reddy's Laboratories3.249 of 5 stars$13.19-0.1%$17.00+28.9%-9.5%$11.01B$311.31B21.0024,800Positive NewsGap DownMRNAModerna4.226 of 5 stars$28.35-8.9%$59.00+108.1%-74.6%$10.96B$3.20B-3.053,900Gap DownHigh Trading VolumeVTRSViatris2.529 of 5 stars$8.71+0.3%$10.50+20.6%-32.1%$10.40B$14.74B-11.7737,000ASNDAscendis Pharma A/S2.9369 of 5 stars$155.86+0.8%$204.64+31.3%+0.4%$9.46B$363.64M-21.951,017Positive NewsGap DownQGENQiagen3.9673 of 5 stars$40.17+0.8%$47.71+18.8%-0.9%$8.91B$1.98B111.866,030Analyst DowngradeROIVRoivant Sciences2.2696 of 5 stars$10.09-2.8%$17.10+69.5%-13.0%$7.20B$122.59M-67.26860LNTHLantheus4.2649 of 5 stars$97.60+1.5%$129.43+32.6%+64.2%$6.68B$1.53B16.24700Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies SMMT Competitors ITCI Competitors GMAB Competitors RDY Competitors MRNA Competitors VTRS Competitors ASND Competitors QGEN Competitors ROIV Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACLX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
